Wellgistics Health, Inc. (WGRX) Financial Statements
Industry: Drugs, Proprietaries & Druggists' Sundries (Wholesale)
In fiscal 2025, Wellgistics Health reported revenue of $23.3M, up 28.7% from $18.1M the year before. Net income was -$101.3M (a -433.9% net margin), or -$71.50 per diluted share. Gross margin was -27.5% and operating margin was -401.7%. Operating activities generated -$10.9M of cash. At fiscal year end, Wellgistics Health held $30.5M in total assets against $42.9M in total liabilities, including $42,571 of cash and equivalents.
Open the full interactive Wellgistics Health financials → Quarterly statements, key ratios, valuation history and price charts.
Wellgistics Health Key Stats
| Share Price | $3.03 |
|---|---|
| Market Cap | $7.8M |
| Revenue YoY Growth | +28.7% |
| 52-Week Range | $0.85 – $57.50 |
| Shares Outstanding | 2.6 million (basic, 2026 Q2) |
Wellgistics Health Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $18.1M | $23.3M |
| Gross Profit | $1.8M | -$6.4M |
| Operating Income | -$6.1M | -$93.7M |
| Pre-Tax Income | -$6.9M | -$101.3M |
| Net Income | -$6.9M | -$101.3M |
| Diluted EPS | -$7.50 | -$71.50 |
Wellgistics Health Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.0M | $1.7M | $1.6M | $1.8M |
| Net Income | -$34.3M | -$27.9M | -$7.7M | -$18.4M |
| Diluted EPS | -$23.00 | -$0.39 | -$3.50 | -$7.13 |
Wellgistics Health Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $1.0M | $42,571 |
| Current Assets | $15.2M | $2.8M |
| Total Assets | $57.3M | $30.5M |
| Current Liabilities | $38.0M | $29.8M |
| Total Long-Term Debt | $23.4M | $23.5M |
| Total Liabilities | $50.6M | $42.9M |
| Shareholders' Equity | $6.7M | -$12.4M |
Wellgistics Health Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$1.2M | -$10.9M |
| Cash From Investing | $469,072 | -$881,526 |
| Cash From Financing | $1.8M | $10.8M |
Figures from Wellgistics Health's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Wellgistics Health financials page for every line item.
Wellgistics Health Company Profile
| Ticker | WGRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Drugs, Proprietaries & Druggists' Sundries (Wholesale) |
| Headquarters | Tampa, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002030763 |
Frequently Asked Questions
What was Wellgistics Health's revenue in fiscal 2025?
Wellgistics Health (WGRX) reported revenue of $23.3M for fiscal 2025.
What was Wellgistics Health's net income in fiscal 2025?
Wellgistics Health reported net income of -$101.3M for fiscal 2025.
What was Wellgistics Health's earnings per share (EPS) in fiscal 2025?
Wellgistics Health's diluted EPS was -$71.50 for fiscal 2025 (adjusted for any later stock splits).
What was Wellgistics Health's revenue last quarter?
In its most recent reported quarter (2026 Q2), Wellgistics Health reported revenue of $1.8M.
How much debt does Wellgistics Health have?
Wellgistics Health reported $23.5M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Wellgistics Health are outstanding?
Wellgistics Health reported a weighted average of 2.6 million basic shares outstanding in 2026 Q2.
What is Wellgistics Health's market cap?
Based on its latest closing price, Wellgistics Health (WGRX) has a market capitalization of about $7.8M.
When does Wellgistics Health's fiscal year end?
Wellgistics Health's fiscal year end, as registered with the SEC, is December 31.
Where is Wellgistics Health headquartered?
Wellgistics Health lists its business address in Tampa, Florida in its SEC filings.